- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 27th, 2005
Starpharma shares soared yesterday after the nanotechnology group confirmed that it had signed a strategic and potentially lucrative deal with The Dow Chemical Company.
Under the three-way deal, Starpharma's US-based subsidiary, Dendritic NanoTechnologies (DNT), will acquire Dow's extensive portfolio of patents covering dendrimer technology. It also gains the rights to revenue from Dow's already established licensing activities.
|Related News Press|
Nanometrics Announces Upcoming Investor Events July 28th, 2015
Self-assembling, biomimetic membranes may aid water filtration August 1st, 2015
Aspen Aerogels to Webcast 2015 Annual Meeting of Stockholders June 11th, 2015
Industrial Nanotech, Inc. Provides Update June 8th, 2015